Petros Pharmaceuticals, Inc.
PTPINASDAQHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$171381
P/E Ratio—
52W High$0.04
52W Low$0.002
Petros Pharmaceuticals, Inc. (PTPI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PTPI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.03
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
PTPI reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q2 FY2026 | May 13, 2026 | — | -$0.03 | — | — | — | — |
| — Q2 FY2026 | Apr 15, 2026 | — | $8.58 | — | — | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | -$0.03 | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$1.58 | — | — | — | — |
| — Q2 FY2025 | May 15, 2025 | — | -$8.46 | — | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$8.25 | -$29.00 | -251.5% | $0.00B | $0.00B | -43.5% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.29 | -$13.25 | -4469.0% | $0.00B | $0.00B | +17.6% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.77 | -$9.25 | -1101.3% | $0.00B | $0.00B | +0.0% |
Q2 FY2026
May 13, 2026
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 15, 2026
EPS Actual
$8.58
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$1.58
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$8.46
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$29.00
EPS Est.
-$8.25
EPS Surpr.
-251.5%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$13.25
EPS Est.
-$0.29
EPS Surpr.
-4469.0%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$9.25
EPS Est.
-$0.77
EPS Surpr.
-1101.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-8.25 | $-8.25 | $-8.25 | 1 |
| Q3 FY2024 | $-7.25 | $-7.25 | $-7.25 | 1 |
| Q2 FY2024 | $-9.25 | $-9.25 | $-9.25 | 1 |
| Q1 FY2024 | $-42.25 | $-42.25 | $-42.25 | 1 |
| Q4 FY2023 | $-1.11 | $-1.11 | $-1.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 13, 2026 | — | $0.01 | $0.01 | +0.00% |
| — Q2 FY2026 | Apr 15, 2026 | — | $0.01 | $0.01 | +0.00% |
| — Q4 FY2025 | Nov 13, 2025 | — | $0.02 | $0.02 | -5.56% |
| — Q3 FY2025 | Aug 14, 2025 | — | $0.03 | $0.03 | +3.33% |
| — Q2 FY2025 | May 15, 2025 | — | $0.14 | $0.16 | +14.29% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -251.5% | $2.15 | $1.73 | -19.53% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -4469.0% | $7.27 | $7.09 | -2.48% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -1101.3% | $7.99 | $7.82 | -2.13% |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q2 FY2026+0.00%
Report Date
Apr 15, 2026
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q4 FY2025-5.56%
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q3 FY2025+3.33%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.03
Q2 FY2025+14.29%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$0.14
Price After
$0.16
Q1 FY2025-19.53%
Report Date
Mar 31, 2025
EPS Beat/Miss
-251.5%
Price Before
$2.15
Price After
$1.73
Q4 FY2024-2.48%
Report Date
Nov 13, 2024
EPS Beat/Miss
-4469.0%
Price Before
$7.27
Price After
$7.09
Q3 FY2024-2.13%
Report Date
Aug 14, 2024
EPS Beat/Miss
-1101.3%
Price Before
$7.99
Price After
$7.82
Avg Miss Reaction-8.05%
Beat Rate0 / 8 quarters
Largest Move-19.53% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PTPI ends December
Petros Pharmaceuticals, Inc. (PTPI) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.03 (in line with the analyst consensus of —). The next PTPI earnings date is expected around September 1, 2026.
Each quarter, investors track PTPI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PTPI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PTPI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PTPI earnings · 4 questionsPetros Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PTPI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PTPI historically reports after market close (AMC).
PTPI earnings datewhen is PTPI earningsPTPI next earnings datewhen does PTPI report earningsPTPI earnings calendar
▸ Source: FMP · Petros Pharmaceuticals, Inc. SEC filings · US GAAP · Petros Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026